Existing and Emerging Targeted Therapies in Juvenile Psoriatic Arthritis: Challenges and Unmet Needs

Area of Science:

• Rheumatology
• Pediatric Rheumatology
• Immunology

Background:

• Juvenile psoriatic arthritis (JPsA) is a complex chronic inflammatory condition in children and young people.
• Heterogeneity in JPsA necessitates tailored therapeutic approaches based on distinct clinical phenotypes.

Purpose of the Study:

• To review challenges in harmonizing JPsA treatment recommendations across different age groups and clinical presentations.
• To explore the evolving therapeutic landscape, including recent clinical trials and ongoing research in JPsA and adult psoriatic arthritis.
• To identify unmet needs and barriers hindering translational research in JPsA.

Main Methods:

• Literature review focusing on JPsA classification, management strategies, and therapeutic advancements.
• Analysis of completed and ongoing clinical trials for novel agents targeting inflammatory pathways (e.g., IL-17, IL-23, JAK).
• Exploration of head-to-head trial data comparing different biologic agents.

Main Results:

• Novel therapies including monoclonal antibodies (anti-IL-17, anti-IL-12/23, anti-IL-23) and small molecules (JAK, TK, PDE4 inhibitors) are under development.
• Many new agents, initially tested in adult psoriatic arthritis, show promising efficacy and safety profiles, advancing to Phase III or gaining approval.
• Head-to-head trials provide comparative data for biologic therapies like TNF-α blockade versus IL-17 and IL-23 inhibitors.

Conclusions:

• Emerging JPsA therapies demonstrate potential for improved efficacy and tolerability, mirroring advancements in adult psoriatic arthritis treatment.
• Further translational research is crucial to understand age-specific treatment efficacy and manage refractory JPsA for better long-term patient outcomes.
• Addressing unmet needs and research barriers will facilitate the translation of novel therapies for JPsA patients.